These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 27624957)
1. Editorial Commentary: Ceftazidime-Avibactam and Carbapenem-Resistant Enterobacteriaceae: "We're Gonna Need a Bigger Boat". Spellberg B; Bonomo RA Clin Infect Dis; 2016 Dec; 63(12):1619-1621. PubMed ID: 27624957 [No Abstract] [Full Text] [Related]
2. Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections. King M; Heil E; Kuriakose S; Bias T; Huang V; El-Beyrouty C; McCoy D; Hiles J; Richards L; Gardner J; Harrington N; Biason K; Gallagher JC Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483952 [TBL] [Abstract][Full Text] [Related]
3. Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation. Krapp F; Grant JL; Sutton SH; Ozer EA; Barr VO Int J Antimicrob Agents; 2017 Jun; 49(6):770-773. PubMed ID: 28389354 [TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam. De la Calle C; Rodríguez O; Morata L; Marco F; Cardozo C; García-Vidal C; Río AD; Feher C; Pellicé M; Puerta-Alcalde P; Mensa J; Soriano A; Martínez JA Int J Antimicrob Agents; 2019 Apr; 53(4):520-524. PubMed ID: 30471403 [TBL] [Abstract][Full Text] [Related]
5. Colistin Does Not Potentiate Ceftazidime-Avibactam Killing of Carbapenem-Resistant Enterobacteriaceae In Vitro or Suppress Emergence of Ceftazidime-Avibactam Resistance. Shields RK; Nguyen MH; Hao B; Kline EG; Clancy CJ Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29891598 [TBL] [Abstract][Full Text] [Related]
6. Activity of Imipenem-Relebactam and Comparator Agents against Genetically Characterized Isolates of Carbapenem-Resistant Enterobacteriaceae. Canver MC; Satlin MJ; Westblade LF; Kreiswirth BN; Chen L; Robertson A; Fauntleroy K; La Spina M; Callan K; Jenkins SG Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262761 [TBL] [Abstract][Full Text] [Related]
8. Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values. Castanheira M; Doyle TB; Hubler C; Sader HS; Mendes RE Int J Antimicrob Agents; 2020 Jul; 56(1):106011. PubMed ID: 32417206 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae. Sousa A; Pérez-Rodríguez MT; Soto A; Rodríguez L; Pérez-Landeiro A; Martínez-Lamas L; Nodar A; Crespo M J Antimicrob Chemother; 2018 Nov; 73(11):3170-3175. PubMed ID: 30099490 [TBL] [Abstract][Full Text] [Related]
10. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae. van Duin D; Lok JJ; Earley M; Cober E; Richter SS; Perez F; Salata RA; Kalayjian RC; Watkins RR; Doi Y; Kaye KS; Fowler VG; Paterson DL; Bonomo RA; Evans S; Clin Infect Dis; 2018 Jan; 66(2):163-171. PubMed ID: 29020404 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae. Alraddadi BM; Saeedi M; Qutub M; Alshukairi A; Hassanien A; Wali G BMC Infect Dis; 2019 Sep; 19(1):772. PubMed ID: 31484510 [TBL] [Abstract][Full Text] [Related]
12. Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Ackley R; Roshdy D; Meredith J; Minor S; Anderson WE; Capraro GA; Polk C Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094128 [TBL] [Abstract][Full Text] [Related]
14. Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae. Haidar G; Clancy CJ; Chen L; Samanta P; Shields RK; Kreiswirth BN; Nguyen MH Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630202 [TBL] [Abstract][Full Text] [Related]
15. Assessing the in vitro activity of ceftazidime/avibactam and aztreonam among carbapenemase-producing Enterobacteriaceae: Defining the zone of hope. Avery LM; Nicolau DP Int J Antimicrob Agents; 2018 Nov; 52(5):688-691. PubMed ID: 30044946 [TBL] [Abstract][Full Text] [Related]
16. In vitro efficacy of ceftazidime-avibactam, aztreonam-avibactam and other rescue antibiotics against carbapenem-resistant Enterobacterales from the Arabian Peninsula. Sonnevend Á; Ghazawi A; Darwish D; Barathan G; Hashmey R; Ashraf T; Rizvi TA; Pál T Int J Infect Dis; 2020 Oct; 99():253-259. PubMed ID: 32738488 [TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755 [TBL] [Abstract][Full Text] [Related]
18. In vivo efficacy of humanized exposures of Ceftazidime-Avibactam in comparison with Ceftazidime against contemporary Enterobacteriaceae isolates. MacVane SH; Crandon JL; Nichols WW; Nicolau DP Antimicrob Agents Chemother; 2014 Nov; 58(11):6913-9. PubMed ID: 25223999 [TBL] [Abstract][Full Text] [Related]
20. Activity of ceftazidime-avibactam against carbapenemase-producing Enterobacteriaceae from urine specimens obtained during the infection-carbapenem resistance evaluation surveillance trial (iCREST) in Spain. García-Castillo M; García-Fernández S; Gómez-Gil R; Pitart C; Oviaño M; Gracia-Ahufinger I; Díaz-Regañón J; Tato M; Cantón R; Int J Antimicrob Agents; 2018 Mar; 51(3):511-515. PubMed ID: 29371104 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]